Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against Omicron SARS-CoV-2

Two doses of the BNT162b2 mRNA vaccine are highly effective against SARS-CoV-2. Here, we tested the antibody neutralization against Omicron SARS-CoV-2 after 2 and 3 doses of BNT162b2. Serum from vaccinated individuals was serially tested for its ability to neutralize wild-type SARS-CoV-2 (USA-WA1/20...

Descripción completa

Detalles Bibliográficos
Autores principales: Xia, Hongjie, Zou, Jing, Kurhade, Chaitanya, Cai, Hui, Yang, Qi, Cutler, Mark, Cooper, David, Muik, Alexander, Jansen, Kathrin U., Xie, Xuping, Swanson, Kena A., Shi, Pei-Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8853806/
https://www.ncbi.nlm.nih.gov/pubmed/35245438
http://dx.doi.org/10.1016/j.chom.2022.02.015
_version_ 1784653306343194624
author Xia, Hongjie
Zou, Jing
Kurhade, Chaitanya
Cai, Hui
Yang, Qi
Cutler, Mark
Cooper, David
Muik, Alexander
Jansen, Kathrin U.
Xie, Xuping
Swanson, Kena A.
Shi, Pei-Yong
author_facet Xia, Hongjie
Zou, Jing
Kurhade, Chaitanya
Cai, Hui
Yang, Qi
Cutler, Mark
Cooper, David
Muik, Alexander
Jansen, Kathrin U.
Xie, Xuping
Swanson, Kena A.
Shi, Pei-Yong
author_sort Xia, Hongjie
collection PubMed
description Two doses of the BNT162b2 mRNA vaccine are highly effective against SARS-CoV-2. Here, we tested the antibody neutralization against Omicron SARS-CoV-2 after 2 and 3 doses of BNT162b2. Serum from vaccinated individuals was serially tested for its ability to neutralize wild-type SARS-CoV-2 (USA-WA1/2020) and an engineered USA-WA1/2020 bearing the Omicron spike glycoprotein. At 2 or 4 weeks post dose 2, the neutralization geometric mean titers (GMTs) against the wild-type and Omicron-spike viruses were 511 and 20, respectively; at 1 month post dose 3, the neutralization GMTs increased to 1,342 and 336; and at 4 months post dose 3, the neutralization GMTs decreased to 820 and 171. The data support a 3-dose vaccination strategy and provide a glimpse into the durability of the neutralization response against Omicron.
format Online
Article
Text
id pubmed-8853806
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-88538062022-02-18 Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against Omicron SARS-CoV-2 Xia, Hongjie Zou, Jing Kurhade, Chaitanya Cai, Hui Yang, Qi Cutler, Mark Cooper, David Muik, Alexander Jansen, Kathrin U. Xie, Xuping Swanson, Kena A. Shi, Pei-Yong Cell Host Microbe Brief Report Two doses of the BNT162b2 mRNA vaccine are highly effective against SARS-CoV-2. Here, we tested the antibody neutralization against Omicron SARS-CoV-2 after 2 and 3 doses of BNT162b2. Serum from vaccinated individuals was serially tested for its ability to neutralize wild-type SARS-CoV-2 (USA-WA1/2020) and an engineered USA-WA1/2020 bearing the Omicron spike glycoprotein. At 2 or 4 weeks post dose 2, the neutralization geometric mean titers (GMTs) against the wild-type and Omicron-spike viruses were 511 and 20, respectively; at 1 month post dose 3, the neutralization GMTs increased to 1,342 and 336; and at 4 months post dose 3, the neutralization GMTs decreased to 820 and 171. The data support a 3-dose vaccination strategy and provide a glimpse into the durability of the neutralization response against Omicron. Elsevier Inc. 2022-04-13 2022-02-18 /pmc/articles/PMC8853806/ /pubmed/35245438 http://dx.doi.org/10.1016/j.chom.2022.02.015 Text en © 2022 Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Brief Report
Xia, Hongjie
Zou, Jing
Kurhade, Chaitanya
Cai, Hui
Yang, Qi
Cutler, Mark
Cooper, David
Muik, Alexander
Jansen, Kathrin U.
Xie, Xuping
Swanson, Kena A.
Shi, Pei-Yong
Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against Omicron SARS-CoV-2
title Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against Omicron SARS-CoV-2
title_full Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against Omicron SARS-CoV-2
title_fullStr Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against Omicron SARS-CoV-2
title_full_unstemmed Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against Omicron SARS-CoV-2
title_short Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against Omicron SARS-CoV-2
title_sort neutralization and durability of 2 or 3 doses of the bnt162b2 vaccine against omicron sars-cov-2
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8853806/
https://www.ncbi.nlm.nih.gov/pubmed/35245438
http://dx.doi.org/10.1016/j.chom.2022.02.015
work_keys_str_mv AT xiahongjie neutralizationanddurabilityof2or3dosesofthebnt162b2vaccineagainstomicronsarscov2
AT zoujing neutralizationanddurabilityof2or3dosesofthebnt162b2vaccineagainstomicronsarscov2
AT kurhadechaitanya neutralizationanddurabilityof2or3dosesofthebnt162b2vaccineagainstomicronsarscov2
AT caihui neutralizationanddurabilityof2or3dosesofthebnt162b2vaccineagainstomicronsarscov2
AT yangqi neutralizationanddurabilityof2or3dosesofthebnt162b2vaccineagainstomicronsarscov2
AT cutlermark neutralizationanddurabilityof2or3dosesofthebnt162b2vaccineagainstomicronsarscov2
AT cooperdavid neutralizationanddurabilityof2or3dosesofthebnt162b2vaccineagainstomicronsarscov2
AT muikalexander neutralizationanddurabilityof2or3dosesofthebnt162b2vaccineagainstomicronsarscov2
AT jansenkathrinu neutralizationanddurabilityof2or3dosesofthebnt162b2vaccineagainstomicronsarscov2
AT xiexuping neutralizationanddurabilityof2or3dosesofthebnt162b2vaccineagainstomicronsarscov2
AT swansonkenaa neutralizationanddurabilityof2or3dosesofthebnt162b2vaccineagainstomicronsarscov2
AT shipeiyong neutralizationanddurabilityof2or3dosesofthebnt162b2vaccineagainstomicronsarscov2

Ejemplares similares